active and latent tb in patients with rheumatic diseases
TRANSCRIPT
![Page 1: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/1.jpg)
Active and Latent TB in the Vulnerable Group:
Persons with Rheumatologic Diseases
Julie T. Li-Yu, MD, MSPH
Juan Javier Lichauco, MD
Philippine Rheumatology Association
![Page 2: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/2.jpg)
![Page 3: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/3.jpg)
![Page 4: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/4.jpg)
Philippine Guidelines Recommendations 2006
• Patients for biologic therapy should be screened for latent and active TB prior to initiating treatment.
• All patients who are candidates for biologic agents should be screened by tuberculin skin test for latent TB, and a chest radiograph for active tuberculosis.
• Household and close contacts of candidate patients should be screened for active tuberculosis.
• All household and close contacts of candidate patients should be screened for active TB using chest radiograph.
• Treat latent and active tuberculosis according to local guidelines. • Delay treatment with biologic agents in patients with latent or
active tuberculosis. • Administer tuberculosis prophylaxis to the patient for biologic
therapy exposed to household contacts with active tuberculosis.
![Page 5: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/5.jpg)
Update on the Phil CPG for the Diagnosis and Treatment of Adult TB 2014
Task Force includes professional and medical societies and government agencies: • Philippine Coalition Against Tuberculosis (PHILCAT) – to
represent non-government organizations not considered professional medical groups
• Philippine Society for Microbiology and Infectious Diseases (PSMID)
• Philippine College of Chest Physicians (PCCP) • Philippine College of Physicians (PCP) • Philippine College of Radiology (PCR) • Philippine Academy of Family Physicians (PAFP) • Philippine College of Occupational Medicine (PCOM) • Department of Health (DOH)
![Page 6: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/6.jpg)
Five (5) major TWCs:
• Committee on Diagnosis
• Committee on Treatment
• Committee on MDR-TB
• Committee on TB-HIV and other Vulnerable Populations
• Committee on Prevention and Control
Committee on TB-HIV and other Vulnerable Groups -
Team Leader: Mario Panaligan, MD (PSMID)
Members:
• PCCP, PSCO, PHS, PSEM, PRA, POGS, PSMID
![Page 7: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/7.jpg)
Objectives/Key Issues Main Issue:
Diagnosis and Management of LTBI and active TB among patients with rheumatic diseases commencing and on biologic agents
Specific issues:
– What is the epidemiology of TB disease in patients with rheumatic diseases?
– How useful is screening for LTBI? • What is the most appropriate screening tool?
• What is the risk of conversion to active TB?
– Among LTBI patients, what is the most suitable chemoprophylactic drug/s? Dose? Duration? Monitor treatment response?
– What is the most appropriate test to diagnose active TB?
– Among patients with active TB, what is the most suitable treatment regimen? Dose? Duration? Monitor treatment response?
– Should we be screening household contacts/co-workers?
– What is the interval time for TB screening while patient is on biologics?
![Page 8: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/8.jpg)
Methodology
• International organizations – ACR 2012, EULAR 2013, APLAR (ongoing) • Country specific guidelines – Hongkong 2011, Portugal 2012, Japan 2007,
Canada 2010, Australian 2010 • Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument • Issues not addressed in international CPGs
– Search engine: Pubmed – Search terms:
Latent tuberculosis etanercept • Guidelines infliximab • Rheumatic diseases adalimumab • Rheumatoid arthritis tocilizumab • Psoriasis rituximab • Spondylarthritis anakinra • Ankylosing spondylitis certolizumab • Biologic therapy
• Limitations: publications in English language • Period: January 2006 to December 2013
![Page 9: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/9.jpg)
Epidemiology
• Incidence of TB among patients with rheumatic diseases
• Review of records of RA patients ± IFX/ETN
– Korea (2001-2004): 67.2/100,000PY (gen pop)
• Naïve TNF blocker RA pts: 257/100,000PY
• IFX treated RA pts: 2558/100,000PY
• ETN treated RA pts: 0/73.67PY
– Risk of TB greater in RA patients RR 8.9 (4.6-17.2) vs IFX users RR 30.1 (7.4-122.3) vs gen pop
Sang-Seokg Seong et al. J Rheumatol 2007;34:706-11
![Page 10: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/10.jpg)
Epidemiology
• National Network of Epidemiological Surveillance Report (Spain 1990-2000)
• Mean incidence of TB 23 cases/100,000
– 7 cases in RA cohort
– Mean annual incidence 134/100,000 patients
– Incidence RR of PTB in RA is 3.68 (2.36-5.92)
Carmona L, et al. Increased risk of tuberculosis among RA patients. J Rheumatol 2003
![Page 11: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/11.jpg)
Epidemiology • Systematic study tertiary referral center (1997-2004) • Incidence rate of serious infections before anti-TNF
therapy (3.4/100PY) vs after 1st dose of anti-TNF (10.5/100PY) = NNH 14
• Multivar analysis: risk factors were prev joint surgery and use of corticosteroids
• US: incidence of TB in general pop 5.8/100,000
• 10,000 RA patients: incidence of TB 6.2/100,000 (biologic
naïve)
Salliot C, et a. Infections during anti-TNF blocker therapy for rheumatic diseases in daily practice. Rheumatology 2007
US Department of Health and Human Services CDC Atlanta 2001
Wolfe et al. Tuberculosis infections in patient with RA and the effect of IFX therapy. Arthritis Rheum 2004
![Page 12: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/12.jpg)
Biologics in Rheumatic Diseases
• 40 cases of TB reported in anti-TNF cohort • Rate of TB in ADA (144/100,000PY), INF (136/100,000PY), ETA
(39/100,000PY) • Median time to event
– INF 5.5 mos, ETA 13.4 mos, ADA 18.5 mos
• Risk of SI in RA patients treated with anti-TNF – Prospective observational study (BSRBR) – 11798 anti-TNF treated patients vs 3598 nbDMARDs – 1808 patients with SI (anti TNF 1512; nbDMARD 296) – Incidence rates: anti-TNF 42/1000PY nbDMARD 32/1000PY – Risk is not different with 3 anti-TNFs – ETN, INF, ADA – aHR for anti-TNF 1.2 (95% CI 1.1, 1.5), risk highest in 1st 6 mos therapy
aHR 1.8 (95% CI1.3, 2.6)
Dixon et al. Drug-specific risk of TB in patients with RA treated with anti-TNF therapy, the BSRBR. ARD 2010
Updated results from BSRBR with special emphasis on risks in the elderly. Rheumatology 2011
![Page 13: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/13.jpg)
Epidemiology
Navarra S, et al. Risk of TB with anti-TNF therapy: substantially higher number of patients at risk in Asia. IJRD 2014
![Page 14: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/14.jpg)
Projected incremental TB risks in Asian countries
Navarra S, et al. Risk of TB with anti-TNF therapy: substantially higher number of patients at risk in Asia. IJRD 2014
![Page 15: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/15.jpg)
Navarra S, et al. Risk of TB with anti-TNF therapy: substantially higher number of patients at risk in Asia. IJRD 2014
![Page 16: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/16.jpg)
AGREE II Guidance for rating each item:
Domain 1: Scope and Purpose (3)
Domain 2: Stakeholder Involvement (3)
Domain 3: Rigor of Development (8)
Domain 4: Clarity of Presentation (3)
Domain 5: Applicability (4)
Domain 6: Editorial Independence (2)
Overall Guideline Assessment
Each item rated on a 7-point rating scale (1-strongly disagree, 7- strongly agree)
A quality score calculated for each domain.
High quality – ≥75% vs low quality - ≤ 25%
2 appraisers
Guideline generally recommended if both reviewers scored it 7, recommended with provision if either 5 or 6, not recommended if ≤ 4.
![Page 17: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/17.jpg)
Recommendation
All patients with rheumatic disease who are candidates for use of biologic therapy should be screened for active and latent tuberculosis infection.
1. How useful is screening for LTBI?
• Summary of Evidence: (AGREE: Recommend = 7) – All 7 guidelines addressed the concern on LTBI
screening (medical history, RF)
• Comments: – There is high quality of evidence to recommend
screening for LTBI in patients starting biologic therapies as part of their RA therapy.
![Page 18: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/18.jpg)
2. What is the best screening tool for LTBI?
Summary of Evidence: (AGREE: Recommend = 7)
• TST – Acr/Aus (2-step)/Can/HK /Japan/ Portuguese/ EULAR
• IGRA – Acr/Aus/Can (false+TST)/Portuguese/EULAR
• Discordance between TST and IGRAs
Recommendation
In the absence of gold standard in diagnosing LTBI, it is recommended to use skin test (TST) on all patients commencing biologic drugs. IGRA maybe an option for those with previous BCG vaccination.
![Page 19: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/19.jpg)
IGRA vs TST in patients with RA
• Objective: analyze results of IGRA and TST to detect LTBI in patients with RA
• Methodology: – Systematic review: 7 studies ( 5 CCS, 2 CSS) – 405 RA, 339 controls – IGRA and/or TST
• Results: – IGRA positivity rate 31.6% (89/282), range 11.4%-44.6% – TST positivity rate 23% (78/339), range 14.6% - 45% – Concordance rate 40%-76%, discordance rate 24%-29.7% – Poor agreement between IGRA and TST in RA (69.6%, k=0.33)
• Recommendations: – Both IGRA and TST are needed to detect LTBI in RA
Song GG, Bae SC, Lee YH. IJRD 2013;16:279-283
![Page 20: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/20.jpg)
Agreement bet IGRA and TST IGRA + IGRA - Total Agreement Kappa
TST + 32 17 49 69.6 0.33
TST – 34 85 119
Total 66 102
Subjects IGRA + /total tested TST +/total tested
RA 72/236 78/316
Control 74/185 200/339
RR (RA vs control) 0.802 (0.629-1.023), p = 0.075
0.680 (0.331-0.339), p = 0.295
IGRA and TST positivity rates among RA vs controls
Song GG, Bae SC, Lee YH. IJRD 2013;16:279-283
![Page 21: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/21.jpg)
3. What is the cut-off for a positive LTBI?
Summary of Evidence:
(AGREE: Recommend w provision = 4, no recommendation = 3)
ACR/EULAR/AusRA)
CanRA ≥5 mm immunosuppressed (10mm cut-off: w/o RF)
HK ≥10mm
Portuguese ≥10mm immunocompetent, ≥5mm immunocompromised
Japan ≥20mm
Recommendation
An induration ≥10 mm is considered positive.
![Page 22: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/22.jpg)
T-cell based assays for the diagnosis of latent tuberculosis infection: an update
Objective: diagnostic accuracy of QFT-G, QFT-GIT, T.SpotTB
Methodology: meta-analysis of 30/38 studies (3/2008)
Results:
• Pooled sensitivity of 22 QFT-G/QFT-GIT 76% (72%-80%) and 13 T.SpotTB 90% (86%-93%)
• Pooled specificity 98% (96%-99%) for all QFT-G and QFT-GIT, 93% (86%-100%) for T.SpotTB
• Heterogenous sensitivity for TST, pooled estimate 77% (71%-82%)
• Pooled specificity (non-BCG vaccinated) 97% (955-99%) vs BCG vaccinated 59% (46%-72%)
Pai M, Zwerling A, Menzies D. Ann Intern Med 2008;149:177-184
![Page 23: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/23.jpg)
TNF antagonists and TB in patients with RA: An Asian perspective
• Low TB burden countries: specificity for T.SpotTB 98%-100% and QFT-GIT 99.4%
• Pooled positive predictive value for IGRA 2.3% to 3.2% and TST 1.2% to 1.7%, increased to 6.8% and 2.4% respectively in high risk groups
• Pooled negative predictive value 99.7% (IGRA) and 99.4% (TST)
• Diel R, et al. Meta-analysis. Of predictive value of IGRA and TST. Chest 2012
• IGRA more superior in predicting TB than TST • T.SpotTB performs better than QFT-GIT in predicting
progression to LTBI esp in immunocompromised patients
To KW, Reino JJG, Yoo DH, Tam LS. Respirology 2013
![Page 24: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/24.jpg)
4. What is the most cost-effective chemoprophylactic drug for LTBI?
Recommendation
Patients screened positive for LTBI should receive 300 mg/day isoniazid for 9 months.
Summary of Evidence:
(AGREE: Recommend = 4, Recommend w provision = 3)
ACR/EULAR – local guidelines
CanRA/HK/Japan/Portuguese – INH x 9 mos (except Japan)
AusRA – INH 5mg/kg/day x 6-9 mos or Rif 10mg/kg/day x 4 mos
![Page 25: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/25.jpg)
Summary of Evidence
Drug Duration
Hongkong 2011 INH *if biologics not urgent, tx x 4 mos
9 mos
ACR 2012 Refer to specialist for treatment
EULAR 2013 According to local guidelines (INH started for a month before bologics)
Australian 2010 INH 5 mkd (max < 300mg/day) + pyridoxine (25 mg/d) 6-9 mos
INH 10 mkd (max 600 mg/day) 4 mos
Canadian 2012 INH 9 mos
Japan 2007 INH 300 mg/day
Portuguese 2012 INH 9 mos
![Page 26: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/26.jpg)
5. What is the interval screening period for patients on biologics?
Summary of Evidence: (AGREE: Recommend = 1, no recommendations = 6) Patients may remain TST or IGRA positive after successful treatment of TB. Monitor patients for clinical signs and symptoms of recurrent TB.
Recommendation
Annual testing in RA patients who live, travel, or work in areas where TB exposure is likely while they continue receiving biologic therapies.
![Page 27: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/27.jpg)
Frequent conversions of TB screening tests during anti-TNF therapy in patients
with rheumatic diseases
• Objective: rate of TB screening test conversion during anti-TNF therapy among baseline negative patients
• Methodology: – Greece (2009-2013)
– Prospective study
– Assays: TST, T-spot TB, QuantiFERON TB Gold in tube (QFT-GIT)
– 70 patients (RA, spondylo, etc)
– Anti-TNFs (ADA, ETN, IFX, Goli, certo) x 1 year
Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, et al. ARD 2014
![Page 28: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/28.jpg)
Results: • 20 (29%): conversion of at least 1 assay after 12 mos
[TST 9 (13%), T-spot TB 7 (10%), QFT-GIT 5 (7%)] • 1 conversion of more than 1 screening test • IFX dec rate of screening test conversion (OR 0.048,
0.004-0.606, p=0.017) • No patient (40% received INH therapy) developed
active TB during follow up (27±12 mos) Conclusion: • 1/3 conversion of screening tests during biologic
therapy Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, et al. ARD 2014
Frequent conversions of TB screening tests during anti-TNF therapy in patients
with rheumatic diseases
![Page 29: Active and Latent TB in Patients with Rheumatic Diseases](https://reader034.vdocuments.net/reader034/viewer/2022042516/55cdf4eebb61eb831b8b4735/html5/thumbnails/29.jpg)
Questions?